United Therapeutics Corporation Capital Expenditures
United Therapeutics Corporation (UTHR) reported Capital Expenditures of $208.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-05
- United Therapeutics Corporation payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $108.00M, a 73.63% increase year-over-year.
- United Therapeutics Corporation payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $100.80M, a 34.58% increase year-over-year.
- United Therapeutics Corporation payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $172.90M, a 99.42% increase year-over-year.
- United Therapeutics Corporation payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $210.50M, a 175.16% increase year-over-year.
- United Therapeutics Corporation payments to acquire property, plant, and equipment for fiscal 2025 was $520.50M, a 111.16% increase from fiscal 2024.
- United Therapeutics Corporation payments to acquire property, plant, and equipment for fiscal 2024 was $246.50M, a 6.99% increase from fiscal 2023.
- United Therapeutics Corporation payments to acquire property, plant, and equipment for fiscal 2023 was $230.40M, a 65.99% increase from fiscal 2022.
- United Therapeutics Corporation payments to acquire property, plant, and equipment for fiscal 2022 was $138.80M, a 14.90% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 3 month as first filed | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 6 month as first filed | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 9 month as first filed | Payments to Acquire Property, Plant, and Equipment 12 month | Payments to Acquire Property, Plant, and Equipment 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $108.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $208.80M 10-Q · filed 2026-08-05 | $381.70M derived: sum of 3 quarters · filed 2026-08-05 | $592.20M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $100.80M 10-Q · filed 2026-05-06 | $273.70M derived: sum of 2 quarters · filed 2026-05-06 | $484.20M derived: sum of 3 quarters · filed 2026-05-06 | $546.40M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $172.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $383.40M derived: sum of 2 quarters · filed 2026-02-25 | $445.60M derived: sum of 3 quarters · filed 2026-08-05 | $520.50M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $210.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $272.70M derived: sum of 2 quarters · filed 2026-08-05 | $347.60M 10-Q · filed 2025-10-29 | $434.30M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $62.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $137.10M 10-Q · filed 2026-08-05 | $223.80M derived: sum of 3 quarters · filed 2026-08-05 | $300.30M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $74.90M 10-Q · filed 2026-05-06 | $161.60M derived: sum of 2 quarters · filed 2026-05-06 | $238.10M derived: sum of 3 quarters · filed 2026-05-06 | $283.20M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $86.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $163.20M derived: sum of 2 quarters · filed 2026-02-25 | $208.30M derived: sum of 3 quarters · filed 2026-02-25 | $246.50M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $76.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $121.60M derived: sum of 2 quarters · filed 2025-10-29 | $159.80M 10-Q · filed 2025-10-29 | $238.50M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $45.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $83.30M 10-Q · filed 2025-07-30 | $162.00M derived: sum of 3 quarters · filed 2026-02-25 | $227.70M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $38.20M 10-Q · filed 2025-04-30 | $116.90M derived: sum of 2 quarters · filed 2026-02-25 | $182.60M derived: sum of 3 quarters · filed 2026-02-25 | $227.30M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $78.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $144.40M derived: sum of 2 quarters · filed 2026-02-25 | $189.10M derived: sum of 3 quarters · filed 2026-02-25 | $230.40M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $65.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $110.40M derived: sum of 2 quarters · filed 2024-10-30 | $151.70M 10-Q · filed 2024-10-30 | $191.20M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | $44.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $86.00M 10-Q · filed 2024-07-31 | $125.50M derived: sum of 3 quarters · filed 2025-02-26 | $194.30M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-03-31 | $41.30M 10-Q · filed 2024-05-01 | $80.80M derived: sum of 2 quarters · filed 2025-02-26 | $149.60M derived: sum of 3 quarters · filed 2025-02-26 | $166.60M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-12-31 | $39.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $108.30M derived: sum of 2 quarters · filed 2025-02-26 | $125.30M derived: sum of 3 quarters · filed 2025-02-26 | $138.80M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | $68.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $85.80M derived: sum of 2 quarters · filed 2023-11-01 | $99.30M 10-Q · filed 2023-11-01 | $169.90M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $17.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $30.50M 10-Q · filed 2023-08-02 | $101.10M derived: sum of 3 quarters · filed 2024-02-21 | $124.40M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | $13.50M 10-Q · filed 2023-05-03 | $84.10M derived: sum of 2 quarters · filed 2024-02-21 | $107.40M derived: sum of 3 quarters · filed 2024-02-21 | $123.70M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $70.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $93.90M derived: sum of 2 quarters · filed 2024-02-21 | $110.20M derived: sum of 3 quarters · filed 2024-02-21 | $120.80M 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | $23.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $39.60M derived: sum of 2 quarters · filed 2022-11-02 | $50.20M 10-Q · filed 2022-11-02 | $62.50M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-06-30 | $16.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $26.90M 10-Q · filed 2022-08-03 | $39.20M derived: sum of 3 quarters · filed 2023-02-22 | $55.00M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-03-31 | $10.60M 10-Q · filed 2022-05-04 | $22.90M derived: sum of 2 quarters · filed 2023-02-22 | $38.70M derived: sum of 3 quarters · filed 2023-02-22 | $56.90M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2020-12-31 | $12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $28.10M derived: sum of 2 quarters · filed 2023-02-22 | $46.30M derived: sum of 3 quarters · filed 2023-02-22 | $59.30M 10-K · filed 2023-02-22 | ||||
| 2020-09-30 | $15.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $34.00M derived: sum of 2 quarters · filed 2021-11-03 | $47.00M 10-Q · filed 2021-11-03 | $71.70M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-06-30 | $18.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $31.20M 10-Q · filed 2021-08-04 | $55.90M derived: sum of 3 quarters · filed 2022-02-24 | $69.50M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-03-31 | $13.00M 10-Q · filed 2021-05-05 | $37.70M derived: sum of 2 quarters · filed 2022-02-24 | $51.30M derived: sum of 3 quarters · filed 2022-02-24 | $71.60M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2019-12-31 | $24.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $38.30M derived: sum of 2 quarters · filed 2022-02-24 | $58.60M derived: sum of 3 quarters · filed 2022-02-24 | $83.70M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $13.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $33.90M derived: sum of 2 quarters · filed 2020-10-28 | $59.00M 10-Q · filed 2020-10-28 | $110.80M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $20.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $45.40M 10-Q · filed 2020-07-29 | $97.20M derived: sum of 3 quarters · filed 2021-02-24 | $138.70M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $25.10M 10-Q · filed 2020-04-29 | $76.90M derived: sum of 2 quarters · filed 2021-02-24 | $118.40M derived: sum of 3 quarters · filed 2021-02-24 | $171.90M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | $51.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $93.30M derived: sum of 2 quarters · filed 2021-02-24 | $146.80M derived: sum of 3 quarters · filed 2021-02-24 | $184.40M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $41.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $95.00M derived: sum of 2 quarters · filed 2019-10-30 | $132.60M 10-Q · filed 2019-10-30 | $160.40M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-06-30 | $53.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $91.10M 10-Q · filed 2019-07-31 | $118.90M derived: sum of 3 quarters · filed 2020-02-26 | $140.90M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | $37.60M 10-Q · filed 2019-05-01 | $65.40M derived: sum of 2 quarters · filed 2020-02-26 | $87.40M derived: sum of 3 quarters · filed 2020-02-26 | $108.30M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $27.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $49.80M derived: sum of 2 quarters · filed 2020-02-26 | $70.70M derived: sum of 3 quarters · filed 2020-02-26 | $86.30M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $22.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $42.90M derived: sum of 2 quarters · filed 2018-10-31 | $58.50M 10-Q · filed 2018-10-31 | $73.20M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | $20.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $36.50M 10-Q · filed 2018-08-01 | $51.20M derived: sum of 3 quarters · filed 2019-02-27 | $60.30M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | $15.60M 10-Q · filed 2018-05-02 | $30.30M derived: sum of 2 quarters · filed 2019-02-27 | $39.40M derived: sum of 3 quarters · filed 2019-02-27 | $49.80M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $14.70M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $23.80M derived: sum of 2 quarters · filed 2019-02-27 | $34.20M derived: sum of 3 quarters · filed 2019-02-27 | $38.00M 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $9.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | $19.50M derived: sum of 2 quarters · filed 2017-10-25 | $23.30M 10-Q · filed 2017-10-25 | $54.80M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-06-30 | $10.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $14.20M 10-Q · filed 2017-07-27 | $45.70M derived: sum of 3 quarters · filed 2018-02-21 | $56.20M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-03-31 | $3.80M 10-Q · filed 2017-04-26 | $35.30M derived: sum of 2 quarters · filed 2018-02-21 | $45.80M derived: sum of 3 quarters · filed 2018-02-21 | $49.60M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2015-12-31 | $31.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $42.00M derived: sum of 2 quarters · filed 2018-02-21 | $45.80M derived: sum of 3 quarters · filed 2018-02-21 | $49.80M 10-K · filed 2018-02-21 | $49.79M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $10.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | $14.30M derived: sum of 2 quarters · filed 2016-10-27 | $18.30M 10-Q · filed 2016-10-27 | $18.26M 10-Q · filed 2015-10-27 | $20.54M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-06-30 | $3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $7.80M 10-Q · filed 2016-07-28 | $7.81M 10-Q · filed 2015-07-28 | $10.04M derived: sum of 3 quarters · filed 2017-02-22 | $23.69M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-03-31 | $4.00M 10-Q · filed 2016-04-28 | $3.98M 10-Q · filed 2015-04-28 | $6.24M derived: sum of 2 quarters · filed 2017-02-22 | $19.89M derived: sum of 3 quarters · filed 2017-02-22 | $32.72M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2014-12-31 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $15.89M derived: sum of 2 quarters · filed 2017-02-22 | $28.72M derived: sum of 3 quarters · filed 2017-02-22 | $47.40M 10-K · filed 2017-02-22 | $47.44M 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $13.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $26.48M derived: sum of 2 quarters · filed 2015-10-27 | $45.16M 10-Q · filed 2015-10-27 | $58.57M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $12.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-28 | $31.51M 10-Q · filed 2015-07-28 | $44.92M derived: sum of 3 quarters · filed 2016-02-25 | $54.34M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $18.68M 10-Q · filed 2015-04-28 | $32.09M derived: sum of 2 quarters · filed 2016-02-25 | $41.51M derived: sum of 3 quarters · filed 2016-02-25 | $46.34M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $13.41M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $22.83M derived: sum of 2 quarters · filed 2016-02-25 | $27.67M derived: sum of 3 quarters · filed 2016-02-25 | $31.91M 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $9.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $14.25M derived: sum of 2 quarters · filed 2014-10-28 | $18.50M 10-Q · filed 2014-10-28 | $39.75M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $4.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | $9.08M 10-Q · filed 2014-07-29 | $30.34M derived: sum of 3 quarters · filed 2015-02-24 | $37.06M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $4.24M 10-Q · filed 2014-04-29 | $25.50M derived: sum of 2 quarters · filed 2015-02-24 | $32.23M derived: sum of 3 quarters · filed 2015-02-24 | $75.87M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | $21.25M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $27.98M derived: sum of 2 quarters · filed 2015-02-24 | $71.62M derived: sum of 3 quarters · filed 2015-02-24 | $111.91M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $6.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $50.37M derived: sum of 2 quarters · filed 2013-10-29 | $90.65M 10-Q · filed 2013-10-29 | $89.90M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $43.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $83.92M 10-Q · filed 2013-07-25 | $83.17M derived: sum of 3 quarters · filed 2014-02-25 | $101.02M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $40.28M 10-Q · filed 2013-04-25 | $39.53M derived: sum of 2 quarters · filed 2014-02-25 | $57.38M derived: sum of 3 quarters · filed 2014-02-25 | $69.92M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | -$747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $17.09M derived: sum of 2 quarters · filed 2014-02-25 | $29.64M derived: sum of 3 quarters · filed 2014-02-25 | $35.98M 10-K · filed 2014-02-25 | $35.98M 10-K · filed 2012-02-28 | |||
| 2011-09-30 | $17.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $30.39M derived: sum of 2 quarters · filed 2012-11-01 | $36.73M 10-Q · filed 2012-11-01 | $42.17M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $12.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $18.88M 10-Q · filed 2012-07-26 | $24.32M derived: sum of 3 quarters · filed 2013-02-26 | $28.41M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $6.34M 10-Q · filed 2012-04-26 | $11.78M derived: sum of 2 quarters · filed 2013-02-26 | $15.86M derived: sum of 3 quarters · filed 2013-02-26 | $18.61M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $5.44M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $9.52M derived: sum of 2 quarters · filed 2013-02-26 | $12.28M derived: sum of 3 quarters · filed 2013-02-26 | $18.64M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $4.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $6.84M derived: sum of 2 quarters · filed 2011-10-27 | $13.20M 10-Q · filed 2011-10-27 | $34.71M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2010-06-30 | $2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $9.12M 10-Q · filed 2011-07-28 | $30.62M derived: sum of 3 quarters · filed 2012-02-28 | $54.68M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2010-03-31 | $6.36M 10-Q · filed 2011-04-28 | $27.87M derived: sum of 2 quarters · filed 2012-02-28 | $51.92M derived: sum of 3 quarters · filed 2012-02-28 | |||||
| 2009-12-31 | $21.51M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $45.56M derived: sum of 2 quarters · filed 2012-02-28 | $95.40M 10-K · filed 2012-02-28 | |||||
| 2009-09-30 | $24.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $73.89M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | $49.84M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | $124.42M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |